Advanced Search
DING Xiaowen, CHEN Feng, XIE Shangnao. Multivariate Analysis of Non-sentinel Lymph Node Status in Breast Cancer Patients with Positive Sentinel Lymph Node[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 864-868. DOI: 10.3971/j.issn.1000-8578.2013.09.011
Citation: DING Xiaowen, CHEN Feng, XIE Shangnao. Multivariate Analysis of Non-sentinel Lymph Node Status in Breast Cancer Patients with Positive Sentinel Lymph Node[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 864-868. DOI: 10.3971/j.issn.1000-8578.2013.09.011

Multivariate Analysis of Non-sentinel Lymph Node Status in Breast Cancer Patients with Positive Sentinel Lymph Node

More Information
  • Received Date: February 27, 2013
  • Revised Date: June 19, 2013
  • Objective To study the factors influencing non-sentinel lymph node (NSLN) status in patients with SLN-positive breast cancer and to establish a predictive model. Methods Clinicopathological data of 285 breast cancer cases with positive sentinel lymph node were collected.The 13 factors were analyzed by Logistic regression.Predictive model was established for judging matastasis.The sensitivity,specificity and accuracy of the Logistic model were calculated. Results Univariate logistic regression revealed significant correlation between six variables and NSLN metastasis.The six variables were tumor size(OR=1.45,P<0.01),size of positive SLNs(OR=2 078.49,P<0.01),number of positive SLNs (OR=2.44,P<0.01),number of negative SLNs (OR=0.19,P<0.01),vascular invasion (OR=11.45,P<0.01),and positive SLN membrane invasion (OR=74.34,P<0.01).The size of primary tumor,vascular invasion,number of negative SLNs and size of positive SLNs as well as its membrane invasion were significantly related to NSLN metastasis (P<0.05).The rate of sensitivity,specificity and correction classified of the logistic model were 92.62%,89.15% and 91.01%,respectively. Conclusion The model of 5 predictive factors are reliable in predicting the NSLN status and guiding clinical treatment in SLN-positive breast cancer.
  • [1]
    Lyman GH,Giuliano AE,Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J].J Clin Oncol,2005,23(30):7703-20.
    [2]
    Rubio IT,Korourian S,Cowan C, et al. Sentinel lymph node biopsy for staging breast cancer[J].Am J Surg,1998,176(6):532-7.
    [3]
    Carlson RW,McCormick B.Update:NCCN breast cancer Clinical Practice Guidelines[J].J Natl Compr Canc Netw,2005,3 Suppl 1:S7-11.
    [4]
    Giuliano AE,Haigh PI,Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer[J].J Clin Oncol,2000,18(13):2553-9.
    [5]
    Turner RR,Ollila DW,Krasne DL,el al.Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma[J].Ann Surg,1997,226(3):271-6.
    [6]
    Kamath VJ,Giuliano R,Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla:a study to evaluate the need for complete axillary lymph node dissection[J].Arch Surg,2001,136(6):688-92.
    [7]
    Sachdev U,Murphy K,Derzie A, et al. Predictors of nonsentinel lymph node metastasis in breast cancer patients[J].Am J Surg,2002,183(3):213-7.
    [8]
    Nakhlis F,Golshan M.Bevacizumab:where do we go from here in breast cancer? [J].Transl Cancer Res,2012,1(1):55-6.
    [9]
    Chen WQ,Zheng RS,Zhang SW, et al. Report of incidence and mortality in China cancer registries,2009[J].Chin J Cancer Res,2013,25(1):10-21.
    [10]
    Zhang BN,Cao XC,Chen JY, et al. Guidelines on the diagnosis and treatment of breast cancer (2011 edition) [J].Gland Surg,2012,1(1):39-61.
    [11]
    Rashid OM,Takabe K.The evolution of the role of surgery in the management of breast cancer lung metastasis[J].J Thorac Dis,2012,4(4):420-4.
    [12]
    Fan F.Sentinel lymph node micrometastases andolated tumor cells in breast cancer:an evolving field[J].Gland Surg,2012,1(1):5-6.
    [13]
    Bernet L,Cano R.Metastatic sentinel node and axillary lymphadenectomy revisited[J].Gland Surg,2012,1(1):7-8.
    [14]
    McLaughlin SA,Wright MJ,Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection:objective measurements [J].J Clin Oncol,2008,26(32):5213-9.
    [15]
    Nelson V,Rademaker A,Kaklamani V.Paradigm of polyendocrine therapy in endocrine responsive breast cancer:the role of fulvestrant[J].Chin Clin Oncol,2013,2(1):10.
    [16]
    Ashikaga T,Krag DN,Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection[J].J Surg Oncol,2010,102(2):111-8.
    [17]
    Shah-Khan M,Boughey JC.Evolution of axillary nodal staging in breast cancer:clinical implications of the ACOSOG Z0011 Trial[J].Cancer Control,2012,19(4):267-76.
    [18]
    Andersson Y,Frisell J,de Boniface J, et al. Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases:evaluation of the tenon score[J].Breast Cancer (Auckl),2012,6:31-8.
    [19]
    Tvedskov TF,Jensen MB,Lisse IM, et al. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node[J].Int J Cancer,2012,131(10):2367-75.
    [20]
    Meretoja TJ,Strien L,Heikkil PS, et al. A simple nomogram to evaluate the risk of nonsentinel node metastases in breast cancer patients with minimal sentinel node involvement[J].Ann Surg Oncol,2012,19(2):567-76.
    [21]
    Meretoja TJ,Leidenius MH,Heikkil PS, et al. International multicenter tool to predict the risk of nonsentinel node metastases in breast cancer[J].J Natl Cancer Inst,2012,104(24):1888-96.
  • Related Articles

    [1]HUANG Yu, CHEN Wenjuan, SHU Jin, WANG Dong. Association of CYP1A1 and CYP1B1 Gene Polymorphisms with TypeⅠEndometrial Cancer in Chinese Women[J]. Cancer Research on Prevention and Treatment, 2018, 45(1): 15-18. DOI: 10.3971/j.issn.1000-8578.2018.17.0728
    [2]YANG Zhaohuan, CAO Lei, HE Bing, PEI Na, WU Jing, ZHANG Xuemei, LIN Jia. Association of Cytochrome P450 2E1-1239G>C Genetic Variation with Prognosis of Metastatic Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(2): 133-136. DOI: 10.3971/j.issn.1000-8578.2016.02.008
    [4]Wang Li, Wei Feng, Nie Weiwei, Tang Lin, Chen Longbang, Guan Xiaoxiang. Systematic Review of Relationship between Genetic Polymorphism of p73 4G14C-4A14T and Susceptibility to Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(05): 526-531. DOI: 10.3971/j.issn.1000-8578.2012.05.008
    [5]MA Wei, ZHANG Bai-jiang, HUA Feng, WANG Li-ning, MENG Long. A Meta Analysis on Relationship between GSTP1 Ile105Val Genetic Polymorphisms and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1311-1315. DOI: 10.3971/j.issn.1000-8578.2011.11.024
    [6]LI Xin-min, PAN Xiao-lin, YANG An-qiang, ZHENG Xing-zheng, ZHOU Qiu-yuan. Correlation between HPV16 E6 and p53Arg72Pro Polymorphisms[J]. Cancer Research on Prevention and Treatment, 2008, 35(09): 613-616. DOI: 10.3971/j.issn.1000-8578.2457
    [7]HUANG Zhao-hui, HUA Dong, LI Li-hua, MAO Yong, WU Xiao-hong. Prognostic Impact of GSTM1 and GSTP1 Polymorphism on Gastric Cancer Patients Treated with Platinum-based Adjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2008, 35(06): 411-413. DOI: 10.3971/j.issn.1000-8578.2331
    [8]WAN G Na, L I Yan, DON G Xiujuan, GUO Wei, WANG Shijie. Association between p16 Gene C540Gand C580T Polymorphisms and Esophageal Squamous Cell Carcinoma and Gastric Cardiac Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2008, 35(01): 58-61. DOI: 10.3971/j.issn.1000-8578.3230
    [9]CAI Lin, ZHENG Zong li. Study on the Relationship between Polymorphism of Cytochrome P4502E1 and Susceptibility of Gastric Cardia Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(07): 438-440. DOI: 10.3971/j.issn.1000-8578.256
    [10]Li ChaoLong. ROLE OF COLON MUCOSA CYTOCHROME P450 IN ACTIVATION OF CARCINOGEN AND THEIR INDUCTION AND INHIBITION[J]. Cancer Research on Prevention and Treatment, 1991, 18(4): 208-210.

Catalog

    Article views (1314) PDF downloads (362) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return